About Theravance Biopharma
Theravance Biopharma is a company based in San Francisco (United States) founded in 2001.. The company has 97 employees as of December 31, 2024. Theravance Biopharma offers products and services including YUPELRI. Theravance Biopharma operates in a competitive market with competitors including Biogen, UCB, Grifols, Kymeratx and PureTech Health, among others.
- Headquarter San Francisco, United States
- Employees 97 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Theravance Biopharma, Inc.
-
Annual Revenue
$64.38 M12.12as on Dec 31, 2024
-
Net Profit
$-56.42 M-2.22as on Dec 31, 2024
-
EBITDA
$-36.42 M22.9as on Dec 31, 2024
-
Latest Funding Round
$250 M (USD), Debt – Conventional
Dec 03, 2018
-
Investors
HHS
& 1 more
-
Employee Count
97
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Theravance Biopharma
Theravance Biopharma is a publicly listed company on the NASDAQ with ticker symbol TBPH in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Theravance Biopharma
Theravance Biopharma offers a comprehensive portfolio of products and services, including YUPELRI. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Treatment for chronic obstructive pulmonary disease through inhalation.
Unlock access to complete
Unlock access to complete
Funding Insights of Theravance Biopharma
- Total Funding Total Funding
- Total Rounds 5
- Last Round Debt – Conventional — $250.0M
-
First Round
First Round
(29 Nov 2010)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2018 | Amount | Debt – Conventional - Theravance Biopharma | Valuation |
investors |
|
| Oct, 2016 | Amount | Post-IPO - Theravance Biopharma | Valuation |
investors |
|
| Jun, 2012 | Amount | Grant - Theravance Biopharma | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Theravance Biopharma
Theravance Biopharma has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include HHS and GSK. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Public health and human services are overseen by HHS.
|
Founded Year | Domain | Location | |
|
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Theravance Biopharma
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Theravance Biopharma
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Theravance Biopharma Comparisons
Competitors of Theravance Biopharma
Theravance Biopharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, UCB, Grifols, Kymeratx and PureTech Health, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| domain | founded_year | HQ Location |
Therapies for immunological and neurological disorders are developed.
|
|
| domain | founded_year | HQ Location |
Plasma-derived therapies are developed to treat multiple diseases.
|
|
| domain | founded_year | HQ Location |
Small molecule protein degraders are developed for various disorders.
|
|
| domain | founded_year | HQ Location |
Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases.
|
|
| domain | founded_year | HQ Location |
Developer of novel protein-based therapeutics using machine learning and biological engineering
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Theravance Biopharma
Frequently Asked Questions about Theravance Biopharma
When was Theravance Biopharma founded?
Theravance Biopharma was founded in 2001 and raised its 1st funding round 9 years after it was founded.
Where is Theravance Biopharma located?
Theravance Biopharma is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Who is the current CEO of Theravance Biopharma?
Rick E Winningham is the current CEO of Theravance Biopharma.
How many employees does Theravance Biopharma have?
As of Dec 31, 2024, the latest employee count at Theravance Biopharma is 97.
What is the annual revenue of Theravance Biopharma?
Annual revenue of Theravance Biopharma is $64.38M as on Dec 31, 2024.
What does Theravance Biopharma do?
Founded in 2001 and headquartered in San Francisco, United States, Theravance Biopharma operates in the biopharmaceutical sector. Focus is placed on developing treatments for inflammatory and immunological conditions, including revefenacin for chronic obstructive pulmonary disease, NEP inhibitors targeting cardiovascular and renal diseases such as heart failure and diabetic nephropathy, and pan-JAK inhibitors like TD-1473 for inflammatory bowel disease, with positive early clinical results observed.
Who are the top competitors of Theravance Biopharma?
Theravance Biopharma's top competitors include ADMA Biologics, BioNTech and Generate Biomedicines.
What products or services does Theravance Biopharma offer?
Theravance Biopharma offers YUPELRI.
Is Theravance Biopharma publicly traded?
Yes, Theravance Biopharma is publicly traded on NASDAQ under the ticker symbol TBPH.
Who are Theravance Biopharma's investors?
What is Theravance Biopharma's ticker symbol?
The ticker symbol of Theravance Biopharma is TBPH on NASDAQ.